Skip to content

Study on the new regimens to shorten the treatment duration of newly diagnose sputum positive pulmonary tuberculosis

Study on the new regimens to shorten the treatment duration of newly diagnose sputum positive pulmonary tuberculosis

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-INR-16009622
Enrollment
Unknown
Registered
2016-10-26
Start date
2017-01-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

tuberculosis

Interventions

Sponsors

Shanghai Pulmonary Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. newly diagnosed untreated pulmonary tuberculosis patients with positive sputum smear; 2. radiological examination of the lungs with lesions; 3. aged between 18 and 65 years; 4. the fasting blood glucose is less than 7.0mmol/L; 5. sputum smear positive, confirmed is Mycobacterium tuberculosisby by MTB/RIF GeneXpert detection sputum culture positive, the identification of bacteria type identification of Mycobacterium tuberculosis. 6. To be able to understand and sign the informed consent form; 7. DST results showed that the first line four drug were all sensitive or only HR resistant multi drug resistant tuberculosis patients.

Exclusion criteria

Exclusion criteria: 1. Pulmonary tuberculosis complicated with extrapulmonary tuberculosis (except tuberculous pleurisy not develop tuberculous empyema); 2. Allergic to any drug in the program; 3. Combined liver, kidney, metabolism, autoimmune diseases, endocrine, blood, nervous system diseases, mental disease, malignant tumor, long-term use of immunosuppressive agents or HIV/AIDS patients; 4. Alcoholics (>10year, and >100g liquor daily); 5. According to the researchers' judgment, patients who are not suitable for the study or who may not be able to reliably participatethe whole course of the study; 6. to participate in other clinical research at the same time; 7. Poor compliance history in other clinical trials.

Design outcomes

Primary

MeasureTime frame
cure rate;

Secondary

MeasureTime frame
Recurrence rate;radiologic improvement rate;

Countries

China

Contacts

Public ContactSha Wei

Shanghai Pulmonary Hospital

13671758200@126.com+86 13671758200

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026